Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 1 天前评分90
正文 · 原文
NSABP B-42 (15-year data): #ESMO26
Extended letrozole reduces distant recurrence, but without a significant OS benefit.
🔹 Node-positive: 4.4% absolute benefit
🔹 Node-negative: 1.6% (not statistically significant)
@OncoAlert #BreastCancer #bcsm
867 浏览 · 29 赞 · 8 转发 · 1 回复
来源：Aya Mohamed | MSc, MD 🎗 · x.com